Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TERESA J JEFFERS

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1871717033
CMS profile
558778
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,364.62

110 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,318.31 107
Education $25.42 2
Consulting Fee $20.89 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TERESA J JEFFERS

NPI 1871717033 · CMS profile ID 558778

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871717033?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TERESA J JEFFERS, NPI 1871717033, CMS profile ID 558778. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871717033?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). TERESA J JEFFERS, NPI 1871717033, CMS profile ID 558778. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871717033?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
TERESA J JEFFERS, NPI 1871717033, CMS profile ID 558778, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871717033?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

110 matching records · $2,364.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 110 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 110.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $8.4507/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588553 CMS
AstraZeneca Pharmaceuticals LP $17.7507/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104264211 CMS
GENZYME CORPORATION $8.3407/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795402 CMS
Grifols USA, LLC $10.3507/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124714365 CMS
GlaxoSmithKline, LLC. $21.5407/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116729240 CMS
GENZYME CORPORATION $33.7607/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795400 CMS
CSL Behring $8.4306/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604601 CMS
Genentech USA, Inc. $28.5506/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133122671 CMS
PFIZER INC. $26.8606/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131711785 CMS
GlaxoSmithKline, LLC. $23.5106/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116609860 CMS
AstraZeneca Pharmaceuticals LP $28.9206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104627372 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.2506/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588545 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.9006/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588549 CMS
GENZYME CORPORATION $21.6106/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795386 CMS
Grifols USA, LLC $21.9205/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124714363 CMS
AstraZeneca Pharmaceuticals LP $18.5505/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105409133 CMS
GlaxoSmithKline, LLC. $9.4605/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116421275 CMS
CSL Behring $7.0005/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604595 CMS
Hikma Pharmaceuticals USA $23.1705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127502693 CMS
GENZYME CORPORATION $21.5905/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795370 CMS
PFIZER INC. $22.1405/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131551068 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.9705/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588542 CMS
GENZYME CORPORATION $24.0904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795352 CMS
CSL Behring $21.0604/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604589 CMS
Phadia US Inc. $150.2904/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1067587294 CMS
AstraZeneca Pharmaceuticals LP $19.4704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104237889 CMS
Phadia US Inc. $7.0804/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1067587292 CMS
Pharming Healthcare, Inc. $18.7404/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132150975 CMS
CSL Behring $8.0004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604585 CMS
GlaxoSmithKline, LLC. $15.7904/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115801213 CMS
BioCryst US Sales Co., LLC $20.9904/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117472866 CMS
Grifols USA, LLC $6.6304/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124714367 CMS
AstraZeneca Pharmaceuticals LP $24.6103/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104439463 CMS
CSL Behring $6.0003/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604579 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.4403/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588534 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.7603/27/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588538 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.6103/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588531 CMS
GlaxoSmithKline, LLC. $5.6503/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116042778 CMS
GlaxoSmithKline, LLC. $2.6203/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116343788 CMS
GENZYME CORPORATION $15.2403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795338 CMS
CSL Behring $5.7503/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604573 CMS
Greer Laboratories, Inc. $19.2703/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131114363 CMS
AstraZeneca Pharmaceuticals LP $17.2202/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105852552 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.3702/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137588527 CMS
CSL Behring $9.0502/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134604565 CMS
GENZYME CORPORATION $27.1502/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795318 CMS
AstraZeneca Pharmaceuticals LP $28.8302/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104478384 CMS
Genentech, Inc. $123.8102/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133122690 CMS
GlaxoSmithKline, LLC. $13.7902/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116064676 CMS
GENZYME CORPORATION $30.4302/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139795320 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $130.99 3
PY2022 $688.64 20
PY2023 $1,734.64 82
PY2024 $2,364.62 110
PY2025 $3,580.94 162

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $81,457.04 35
PY2024 Principal investigator $30,173.85 9
PY2023 Principal investigator $47,347.14 18
PY2020 Principal investigator $4,262.39 2
PY2019 Principal investigator $20,389.68 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,660.25 12/04/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202528046
Principal investigator 1 ABBVIE INC. $3,195.70 11/05/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202521903
Principal investigator 1 ABBVIE INC. $154.00 10/09/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514435
Principal investigator 1 ABBVIE INC. $3,670.90 10/09/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514631
Principal investigator 1 ABBVIE INC. $784.00 10/09/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514633
Principal investigator 1 ABBVIE INC. $784.00 10/09/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514635
Principal investigator 1 ABBVIE INC. $154.00 10/09/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514637
Principal investigator 1 ABBVIE INC. $20.81 09/16/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202510988
Principal investigator 1 ABBVIE INC. $15,961.80 09/04/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202508506
Principal investigator 1 ABBVIE INC. $870.75 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505183
Principal investigator 1 ABBVIE INC. $54.71 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505185
Principal investigator 1 ABBVIE INC. $784.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505187
Principal investigator 1 ABBVIE INC. $50.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505189
Principal investigator 1 ABBVIE INC. $81.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505191
Principal investigator 1 ABBVIE INC. $300.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505193
Principal investigator 1 ABBVIE INC. $919.35 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505255
Principal investigator 1 ABBVIE INC. $784.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505261
Principal investigator 1 ABBVIE INC. $784.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505263
Principal investigator 1 ABBVIE INC. $52.39 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505265
Principal investigator 1 ABBVIE INC. $784.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505267
Principal investigator 1 ABBVIE INC. $738.45 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505269
Principal investigator 1 ABBVIE INC. $279.45 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505273
Principal investigator 1 ABBVIE INC. $828.90 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505275
Principal investigator 1 ABBVIE INC. $1,004.40 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505277
Principal investigator 1 ABBVIE INC. $5,000.00 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505279
Principal investigator 1 ABBVIE INC. $460.35 08/20/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202505281
Principal investigator 1 ABBVIE INC. $3,642.80 08/06/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202503363
Principal investigator 1 ABBVIE INC. $10,996.80 07/02/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202495571
Principal investigator 1 ABBVIE INC. $42.47 06/26/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202493175
Principal investigator 1 ABBVIE INC. $462.00 06/26/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202493179
Principal investigator 1 ABBVIE INC. $20.81 06/18/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202492119
Principal investigator 1 ABBVIE INC. $125.00 06/03/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202487785
Principal investigator 1 ABBVIE INC. $75.00 05/21/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202485631
Principal investigator 1 ABBVIE INC. $3,393.60 05/07/2025 Non-covered Recipient Entity
CCRAP HOLDINGS PLLC
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202482993
Principal investigator 1 AstraZeneca UK Limited $18,537.35 02/07/2025 Non-covered Recipient Entity
APPLIED RESEARCH CENTER OF ARKANSAS
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185552793